Roth Capital Still Positive on Celldex (CLDX) Upon Completion of Phase III ACT IV Enrollment
Tweet Send to a Friend
Roth Capital affirms Celldex Therapeutics (Nasdaq: CLDX) at Focus Pick/Buy with a price target of $43 following news that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
